Jonathan Allan, GENERAL COUNSEL & Corporate Secretary at Stoke Therapeutics, Inc. (STOK), sold 18,586 shares at $33.64 ($626K) on 2026-03-20, disclosed to the SEC on 2026-03-24.
Scheduled sale ($626k) by GENERAL COUNSEL & Corporate Secretary under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $33.64 | 8,692 | $292K | 46.7% |
| 2 | $33.64 | 8,692 | $292K | 46.7% |
| 3 | $34.41 | 601 | $21K | 3.3% |
| 4 | $34.41 | 601 | $21K | 3.3% |
| Total | $33.69 avg | 18,586 | $626K | 100% |
| Filing → |
| STOK | SELL | 2026-06-18 | $44K | — | Filing → |
| STOK | SELL | 2026-03-19 | $569K | — | Filing → |
| STOK | SELL | 2025-12-10 | $216K | — | Filing → |